Report error Found 21 Enz. Inhib. hit(s) with all data for entry = 50012989
TargetVasopressin V2 receptor(Rat)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Binding affinity towards V2 receptorMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 11nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 12nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 13nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 15nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 20nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 44nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 70nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 91nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 150nMAssay Description:Binding affinity towards human V1a receptorsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 170nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 180nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 190nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 210nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 330nMAssay Description:Inhibitory activity of the human V2 receptor was assessed by the accumulation of cAMP in transfected HEK-293 cells.More data for this Ligand-Target Pair
TargetVasopressin V2 receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 550nMAssay Description:Displacement of [3H]-AVP from human V2 receptors expressed in HEK-293 cellsMore data for this Ligand-Target Pair
TargetVasopressin V1a receptor(Human)
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataIC50: 3.10E+3nMAssay Description:Binding affinity towards VIa receptorMore data for this Ligand-Target Pair